ZYTIGA (abiraterone acetate) - Articles and news items

Professor Paul Workman, Chief Executive of The Institute of Cancer Research

Statement on the rejection of abiraterone before chemotherapy by the Scottish Medicines Consortium

Industry news / 10 February 2015 / The Institute of Cancer Research

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “We’re very disappointed that Scottish men with prostate cancer will miss out on the chance to have abiraterone much earlier in their course of treatment as a result of this decision…”

Johnson & Johnson logo

Johnson & Johnson reports 2014 first-quarter results

Industry news / 15 April 2014 / Johnson & Johnson

Johnson & Johnson announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013…


AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment

Industry news / 11 October 2013 / AstraZeneca

AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer…

Johnson & Johnson logo

Johnson & Johnson completes acquisition of Aragon Pharmaceuticals, Inc.

Industry news, News / 19 August 2013 / Johnson & Johnson

Late-stage prostate cancer treatment strengthens oncology pipeline..

Janssen-Cilag International NV Logo

ZYTIGA® approved in the EU

Industry news, News / 11 January 2013 / Johnson & Johnson

Janssen announced that the EC has approved an extension to the license of the oral, once-daily medication ZYTIGA®…

Johnson & Johnson logo

Late-breaking ASCO data demonstrate circulating tumor cells as potential biomarker for metastatic prostate cancer clinical trials

Industry news, News / 4 June 2011 / Johnson & Johnson

This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...